← Back to patent-cliff list
Gemcitabine controlled release (TARIS Biomedical)
Tier C — Watch / tradeGemcitabine controlled release (TARIS Biomedical)
AstraZeneca
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：RNR, DNA
Indications (approved)：Bladder cancer
Regional status
US
Approved
2025-09-09
EU
Phase III
2020-12-07
China
Phase III
2020-12-07
Japan
Phase III
2020-12-07
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Gemcitabine controlled release (TARIS Biomedical)?
Approved indications include: Bladder cancer.
When does the Gemcitabine controlled release (TARIS Biomedical) patent expire?
No public expiry year is available for Gemcitabine controlled release (TARIS Biomedical) yet; this page updates once verified.
How do I get a quote for Gemcitabine controlled release (TARIS Biomedical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01